Skip to main content
Clinical Trials/NL-OMON45131
NL-OMON45131
Completed
Not Applicable

A prospective randomized multicentre efficacy study on defining the optimal cryoballoon duration therapy for treatment of atrial fibrillation: The 1-2-3 study - The 1-2-3 study

Medisch Spectrum Twente0 sites222 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
Medisch Spectrum Twente
Enrollment
222
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • \* Paroxysmal atrial fibrillation eligible for PVI according to current international guidelines.
  • \* Age \< 75 years.
  • \* Willing and able to sign informed consent.
  • \* Willing to and capable of following the requested study procedures.

Exclusion Criteria

  • \* Age \< 18 years.
  • \* Pregnancy
  • \* Life or follow\-up expectancy \< 12 months.
  • \* Previous PVI.
  • \* Contrast allergy.
  • \* Creatin clearance level \< 60\.
  • \* LVEF \< 40%
  • \* Abnormal left atrium anatomy defined as number of PV\*s \* 2 per side or LA diameter \>50mm (measured in the parasternal long axis, as assessed with transthoracic echocardiography) or \>40cc/m2\. This will lead to exclusion after inclusion but before randomisation.

Outcomes

Primary Outcomes

Not specified

Similar Trials